AM Cortisol Medication-Driven Changes: What Moves the Number and Why It Matters

What Is the Normal and Optimal AM Cortisol Range?

Serum cortisol follows a strong circadian rhythm, peaking within 30 to 60 minutes of waking in what researchers call the cortisol awakening response. The reference interval for a morning draw collected between 8:00 and 9:00 a.m. Is 10 to 20 mcg/dL (275 to 550 nmol/L) by most major laboratory standards [1]. Values above 18 mcg/dL effectively rule out primary adrenal insufficiency without additional testing, according to the 2016 Endocrine Society Clinical Practice Guideline on adrenal insufficiency [2].

Why "Normal" and "Optimal" Are Not the Same

Endocrinologists practicing longevity and precision medicine often target the upper half of the reference interval, roughly 15 to 20 mcg/dL, because values in the low-normal range (10 to 14 mcg/dL) can still reflect partial HPA suppression or suboptimal adrenal reserve. A value of 10 mcg/dL clears the laboratory flag but may leave a patient symptomatic with fatigue, orthostatic hypotension, and salt craving.

The Diagnostic Thresholds That Guide Clinical Action

The Endocrine Society guideline states: "A morning serum cortisol concentration of less than 3 mcg/dL (83 nmol/L) in a symptomatic patient is strongly suggestive of adrenal insufficiency" [2]. Values between 3 and 18 mcg/dL are indeterminate and require the 250 mcg cosyntropin stimulation test for confirmation. A peak stimulated cortisol below 18 mcg/dL at 30 or 60 minutes meets diagnostic criteria for adrenal insufficiency.

How Glucocorticoids Suppress AM Cortisol

Exogenous glucocorticoids are the single most common pharmacologic cause of suppressed AM cortisol. They act at the hypothalamus and pituitary to reduce corticotropin-releasing hormone (CRH) and ACTH secretion, thereby starving the adrenal cortex of its primary trophic signal [3].

Oral and Injectable Steroids

Prednisone at doses as low as 5 mg/day can begin suppressing the HPA axis within 5 to 7 days [4]. A 2012 analysis published in the Annals of the Rheumatic Diseases found measurable HPA suppression (AM cortisol <10 mcg/dL) in 45% of patients taking prednisone at a mean dose of 7.6 mg/day for longer than 3 months [5]. Triamcinolone acetonide injections, including intra-articular doses, carry a recognized risk of suppression lasting 4 to 6 weeks per injection [6].

Inhaled and Intranasal Corticosteroids

Suppression from inhaled corticosteroids is dose-dependent and often underestimated. Fluticasone propionate at 1,000 mcg/day produces measurable AM cortisol suppression in adults, with mean morning cortisol reductions of 27 to 35% compared to baseline in controlled studies [7]. Budesonide at 800 mcg/day shows a smaller but still statistically significant effect. Intranasal fluticasone at standard doses (200 mcg/day) produces minimal systemic suppression in most adults, though children appear more susceptible [8].

Topical Corticosteroids and Suppositories

High-potency topical agents applied to large skin surface areas, occluded skin, or mucous membranes do cross systemically. Clobetasol propionate 0.05% applied twice daily to more than 30% of body surface area has been reported to suppress morning cortisol below 5 mcg/dL [9]. Rectal hydrocortisone suppositories used for inflammatory bowel disease carry a lower but non-zero suppression risk at doses above 100 mg/day.

Progestins, Androgens, and Reproductive Hormones

Megestrol Acetate and Medroxyprogesterone

Megestrol acetate, used for cancer cachexia and appetite stimulation, has clinically significant glucocorticoid-like activity. A key study found that 45 of 47 patients (96%) taking megestrol acetate 800 mg/day had blunted cosyntropin stimulation responses, with mean basal AM cortisol falling to 2.8 mcg/dL [10]. The FDA prescribing information for Megace carries a warning for adrenal insufficiency, specifically noting that "new or worsening adrenal insufficiency has been reported" [11].

Depot medroxyprogesterone acetate (DMPA, Depo-Provera) at 150 mg IM suppresses AM cortisol through similar glucocorticoid receptor cross-reactivity. Studies show AM cortisol suppression persisting for up to 12 weeks after a single injection [12].

Oral Contraceptives and Estrogen Therapy

Oral contraceptives containing ethinyl estradiol raise cortisol-binding globulin (CBG) substantially, which inflates total serum cortisol without changing free (biologically active) cortisol. Women on combined oral contraceptives may show AM cortisol values of 25 to 35 mcg/dL while having entirely normal free cortisol and no adrenal pathology [13]. This effect reverses within approximately 6 weeks of stopping the pill. When testing a patient on estrogen-containing therapy, salivary or free serum cortisol avoids CBG interference.

Opioids and HPA Axis Suppression

Chronic opioid use is a recognized cause of opioid-induced endocrinopathy. Opioids bind mu-receptors in the hypothalamus and suppress CRH release, reducing downstream ACTH and cortisol output [14]. A 2018 systematic review in Pain Medicine (pooled N = 3,214) found that secondary adrenal insufficiency occurred in approximately 9% of patients on chronic oral opioids, with higher rates at morphine-equivalent daily doses above 60 mg [15].

Which Opioids Carry the Highest Risk?

Long-acting oral formulations (extended-release oxycodone, methadone, extended-release morphine) carry higher suppression risk than short-acting agents due to sustained receptor occupancy. Intrathecal opioid delivery carries the highest reported rates of secondary adrenal insufficiency, with some series reporting AM cortisol <3 mcg/dL in up to 15% of patients [16].

Clinical Implications for Telehealth Prescribers

Any patient on chronic opioids who presents with unexplained fatigue, weight loss, hypotension, or recurrent hyponatremia warrants an AM cortisol draw before attributing symptoms to opioid side effects alone.

Antifungal Azoles: Ketoconazole and Beyond

Ketoconazole inhibits CYP11B1 and CYP11A1, two enzymes essential for cortisol biosynthesis in the adrenal cortex. Oral ketoconazole at 400 to 800 mg/day reduces 24-hour urinary free cortisol by 50 to 90% and is still used intentionally to lower cortisol in Cushing syndrome [17]. AM cortisol values below 3 mcg/dL are common at therapeutic doses.

Fluconazole and itraconazole cause milder CYP11 inhibition, but clinically significant AM cortisol reductions have been reported with fluconazole at doses above 400 mg/day used for systemic fungal infections [18]. Voriconazole shows a similar pattern. Patients on prolonged high-dose azole therapy should have baseline and periodic AM cortisol monitoring.

Drugs That Raise AM Cortisol or Interfere With Assays

Not all medication effects produce falsely low cortisol. Several drugs raise measured cortisol or interfere with immunoassay accuracy.

Synthetic Steroids That Cross-React With Cortisol Assays

Prednisolone cross-reacts with many cortisol immunoassays at rates of 10 to 40%, producing spuriously elevated results [19]. Hydrocortisone (cortisol itself) given as replacement therapy obviously elevates measured serum cortisol and must be withheld for 18 to 24 hours before a diagnostic AM draw. The Endocrine Society 2016 guideline recommends switching patients to dexamethasone the evening before testing when assessing HPA axis status, because dexamethasone does not cross-react with standard cortisol immunoassays [2].

Carbamazepine and Other CYP3A4 Inducers

Carbamazepine, rifampin, and phenytoin induce CYP3A4, accelerating cortisol catabolism and occasionally producing low-normal AM cortisol values. More importantly, these drugs reduce dexamethasone bioavailability, making the overnight 1-mg dexamethasone suppression test unreliable in patients taking them [20].

Spironolactone

Spironolactone at doses used for heart failure (25 to 200 mg/day) inhibits 11-beta-hydroxysteroid dehydrogenase and modestly raises free cortisol. The effect is typically small (1 to 3 mcg/dL above baseline) and rarely produces clinical hyperadrenalism, but it can confound borderline results [21].

How to Interpret AM Cortisol in a Medicated Patient: A Step-by-Step Framework

The following decision framework guides interpretation when a patient's medication list complicates a routine AM cortisol result.

Step 1. Identify All Glucocorticoid Sources

Before interpreting any AM cortisol value, compile a complete list of glucocorticoid exposures: oral, inhaled, intranasal, topical, intra-articular, epidural, and suppository. Patients and their dispensing pharmacies frequently omit inhaled and topical agents when listing "steroids."

Step 2. Classify the Direction of the Interference

Assign each relevant medication to one of three categories:

• Suppressor: Lowers AM cortisol (glucocorticoids, megestrol acetate, DMPA, opioids, ketoconazole).
• Inflator: Raises total but not free cortisol (oral estrogens, oral contraceptives).
• Assay interferer: Produces false-high readings on immunoassay (prednisolone, hydrocortisone).

Step 3. Decide Whether to Retest or Proceed to Stimulation Testing

If the suppressor was a short-acting oral glucocorticoid, retest after a 4-week taper and washout. If the patient cannot safely stop the medication, proceed directly to a 250 mcg cosyntropin stimulation test and interpret the peak response (goal: peak cortisol >18 mcg/dL at 30 minutes). If estrogens are elevating CBG, order salivary cortisol or a late-night salivary cortisol pair rather than serum total cortisol.

Step 4. Document Timing and Collection Conditions

AM cortisol results drawn outside the 8:00 to 9:00 a.m. Window are difficult to interpret. A 10:00 a.m. Draw in a normal adult may show cortisol at 8 to 12 mcg/dL and create false concern. The specimen label must record exact draw time, and the ordering provider should flag any result collected after 9:30 a.m. For repeat testing.

Adrenal Insufficiency Screening: When to Order AM Cortisol in a Medicated Patient

The 2016 Endocrine Society guideline recommends AM cortisol screening for any patient who has received supraphysiologic glucocorticoid doses for more than 4 weeks and is now experiencing symptoms consistent with adrenal insufficiency [2]. Symptoms include fatigue, anorexia, nausea, abdominal pain, hypotension, hyponatremia, and eosinophilia.

Screening is also appropriate for patients on megestrol acetate, chronic opioids, or high-dose azole antifungals who develop any of the above symptoms. A value above 18 mcg/dL drawn correctly at 8:00 to 9:00 a.m. Reassures against clinically significant suppression. A value below 3 mcg/dL in a symptomatic patient warrants urgent endocrinology referral and potentially empirical hydrocortisone coverage while confirmatory testing proceeds.

A 2015 Cochrane review on glucocorticoid withdrawal noted that "the risk of adrenal insufficiency is probably underestimated in clinical practice" and that systematic biochemical screening detects suppression in patients who are completely asymptomatic, supporting routine testing over symptom-triggered testing in high-risk groups [22].

Special Populations: TRT, GLP-1 Agonists, and Peptide Therapy

Testosterone Replacement Therapy

Testosterone at standard replacement doses (50 to 100 mg/week IM or 50 to 100 mg/day transdermal) does not directly suppress HPA axis cortisol output. Supraphysiologic testosterone use, as seen in anabolic steroid misuse, may modestly suppress AM cortisol through unclear mechanisms, though the evidence base is limited to small observational series [23].

GLP-1 Receptor Agonists

Semaglutide and liraglutide do not directly affect cortisol synthesis or CBG levels. In the STEP-1 trial (N = 1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo [24]. Body fat loss of this magnitude reduces adipose-based cortisol regeneration (11-beta-HSD1 activity in adipose tissue), which could theoretically lower peripheral cortisol exposure without changing AM serum cortisol measurably. No direct effect on AM cortisol has been demonstrated in the published STEP program data.

Peptides: BPC-157 and Thymosin

Neither BPC-157 nor thymosin alpha-1 has been shown in human trials to alter adrenal cortisol output. Published evidence is largely preclinical, so no clinical cortisol monitoring adjustment is warranted based on these agents alone.

Drug Washout Timing: How Long to Wait Before Retesting

Knowing when to retest is as practical as knowing why cortisol changed.

| Medication Class | Typical Washout Before AM Cortisol Retest | |---|---| | Oral prednisone (physiologic taper complete) | 2 to 4 weeks | | Depot triamcinolone (single joint injection) | 4 to 6 weeks | | Megestrol acetate 800 mg/day | 6 to 8 weeks | | Depot medroxyprogesterone 150 mg IM | 10 to 14 weeks | | Combined oral contraceptive (CBG normalization) | 4 to 6 weeks | | High-dose inhaled fluticasone (>500 mcg/day) | 4 weeks | | Oral ketoconazole | 1 to 2 weeks | | Chronic opioid (adrenal function recovery) | Variable; may require stimulation test while on drug |

These intervals are derived from pharmacokinetic data and clinical endocrinology practice guidelines [2, 4, 12]. Individual recovery may vary based on dose duration, hepatic function, and body composition.

Ordering AM Cortisol Correctly: Practical Lab Protocol

Specimen quality matters as much as timing. Serum (gold-top or red-top tube) is standard for most immunoassays. EDTA plasma produces systematically different results on some platforms and should be avoided unless the laboratory has validated it. The patient should be asked to:

1. Fast from midnight (water is acceptable).
2. Arrive at the draw site between 8:00 and 9:00 a.m.
3. Avoid vigorous exercise the morning of the draw, which can acutely raise cortisol.
4. Withhold hydrocortisone or cortisone acetate replacement doses that morning until after the draw.
5. Note on the requisition any glucocorticoid-containing medications, including inhalers and topicals.

Salivary cortisol collected at home between 8:00 and 9:00 a.m. Correlates well with serum free cortisol and avoids CBG confounding, though reference intervals differ by assay platform and require laboratory-specific interpretation [25].